FAIR VALUE MEASUREMENTS (Details) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
Mar. 31, 2010 USD ($) $ / shares	Dec. 31, 2019 USD ($) payment item	Dec. 31, 2018 USD ($) item
Fair Value Measurement [Line Items]
Cumulative Liability		$ 19.3	$ 18.4
Manhattan and Ariston Pharmaceuticals Merger [Member]
Fair Value Measurement [Line Items]
Notes Issued	$ 15.5
Debt Instrument convertible conversion price \| $ / shares	$ 1,125
Percentage Of Cash Proceeds From Operation To Repay Convertible Debt	50.00%
Debt Instrument, Term	5 years
Debt instrument period	5.00%
Convertible Notes Payable [Member]
Fair Value Measurement [Line Items]
Cumulative Liability		$ 19.3	$ 18.4
Debt Instrument convertible conversion price \| $ / shares	$ 1,125
Percentage Of Cash Proceeds From Operation To Repay Convertible Debt	50.00%
Debt instrument period	5.00%	5.00%	5.00%
Number of payments \| payment		0
Number of obligations \| item		0	0

No definition available.

Name:	tgtx_CumulativeLiabilityOfNote
Namespace Prefix:	tgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	tgtx_FairValueMeasurementLineItems
Namespace Prefix:	tgtx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Refers to the number of obligations.

+ References

No definition available.

+ Details

Name:	tgtx_NumberOfObligations
Namespace Prefix:	tgtx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The number of payment made.

+ References

No definition available.

+ Details

Name:	tgtx_NumberOfPayments
Namespace Prefix:	tgtx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt.

+ References

No definition available.

+ Details

Name:	tgtx_PercentageOfCashProceedsFromOperationToRepayConvertibleDebt
Namespace Prefix:	tgtx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The price per share of the conversion feature embedded in the debt instrument.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870

+ Details

Name:	us-gaap_DebtInstrumentConvertibleConversionPrice1
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

The average effective interest rate during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentInterestRateDuringPeriod
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_DebtInstrumentTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The fair value of notes issued in noncash investing and financing activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

+ Details

Name:	us-gaap_NotesIssued1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=tgtx_ManhattanAndAristonPharmaceuticalsMergerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: